Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) (NATHAN1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00977483
Recruitment Status : Completed
First Posted : September 15, 2009
Last Update Posted : November 30, 2016
Clinquest, Inc.
Quintiles, Inc.
Information provided by:
MEDA Pharma GmbH & Co. KG

September 14, 2009
September 15, 2009
November 30, 2016
May 1998
January 2005   (Final data collection date for primary outcome measure)
Primary efficacy variable: Absolute change in the neuropathy impairment score lower limbs enlarged by 7 objective items (NISLL+7) between baseline (mean of Visit 0.3 and 0.4 or last available value before randomisation, respectively) and endpoint [ Time Frame: 4 years ]
Same as current
Complete list of historical versions of study NCT00977483 on Archive Site
NIS, NSC, TSS, LLF, QST, VDT, CDT and HP, QAE by means of the HRDB, amplitude CMAP, DL and MNCV on peroneal and tibial nerves, amplitude SNAP and latency on sural nerve, foot inspection, efficacy. [ Time Frame: 4 years ]
Same as current
Not Provided
Not Provided
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) NATHAN1 A Randomized, Placebo-controlled, Double-blind Multi-centre Trial With 2 Parallel Groups
To assess clinical efficacy and safety of long-term orally administered thioctic acid in the treatment of diabetic polyneuropathy.
Stage 1 or 2a diabetic (poly)neuropathy (DNP) (Appendix 3) in patients with diabetes mellitus (type I or II); neuropathy impairment score of the lower limbs, enlarged by 7 objective items (NISLL+7) ≥ 97.5 percentile (corresponding to 4.43 score points); total symptoms score of the feet (TSSfeet) ≤ 5.
Phase 3
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Diabetic Polyneuropathy
  • Drug: Thioctic Acid
    600mg tablet once daily 4 years double-blind treatment period
    Other Name: alpha-lipocic acid
  • Drug: Placebo
    1 tablet once daily 4 years double-blind treatment period
  • Experimental: Drug: Thioctic Acid
    600mg tablet Thioctic Acid (alpha-lipoic acid) once daily throughout the trial
    Intervention: Drug: Thioctic Acid
  • Placebo Comparator: Drug: Placebo
    1 tablet once daily throughout the trial
    Intervention: Drug: Placebo
Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schütte K, Dyck PJ. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054-60. doi: 10.2337/dc11-0503. Epub 2011 Jul 20.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
January 2005
January 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Signed Informed Consent. Patients must have willingness and complete competence to cooperate and language barriers must not preclude adequate understanding
  2. Diabetes mellitus (Type I or II), as defined by the American Diabetes Association 1997, lasting > 1 year
  3. Males or females 18 to 64 years (older patients are excluded because of age-related changes in reflexes, quantitative sensory testing endpoints, and nerve conduction endpoints)
  4. Patient must have a symmetric sensory-motor peripheral polyneuropathy attributable to diabetes mellitus following a thorough evaluation for other causes of neuropathy determined by performing complete medical and neurological examinations including physical and neurological history, history of medications, history of exposure to other toxins, and laboratory studies
  5. Severity of diabetic polyneuropathy must be Stage 1 or 2a
  6. Insulin regimen, weight, diet, and activity level must be relatively stable in the opinion of the investigator (for example, HbA1C must not vary by more than ± 2 Vol.% within 6 months preceding the study i.e. if the index measure = 10% the range would be 8-12%)
  7. NIS[LL]+7 tests ≥ 97.5 percentiles (corresponding to 4.43 transformed score points)
  8. NIS[LL] ≥ 2 points (NIS[LL] is based on questions 17-24, 28, 29, 34, 35, and 37 of the NIS)
  9. One of the following:

    • an abnormality of nerve conduction attributes in two separate nerves, i.e. ≥99th percentile for DL or ≤1st percentile for NCV or amplitude or
    • an abnormality of HRDB, i.e. ≤ 1st percentile
  10. TSS (feet) ≤5
  11. Females must either be surgically sterilised (tubal ligation, bilateral oophorectomy, or hysterectomy) or at least 1 year postmenopausal or practicing an acceptable method of contraception, including oral contraceptives with a stable regimen for at least two months, depo-medroxyprogesterone, a barrier method alone (diaphragm, condoms, or contraceptive sponge with spermicidals), or an IUD that has been in place for at least two months

Exclusion Criteria:

  1. Patients with proximal asymmetric neuropathy, cranial neuropathies, truncal radiculopathy, pan dysautonomia, diabetic plexopathies, or acute or active mononeuropathies (including cranial neuropathies, post-herpetic neuralgias, etc.), the presence of which might obscure accurate assessment of severity of the diabetic polyneuropathy under assessment, with the exception of carpal tunnel syndrome (CTS) or tardy ulnar neuropathy (TUN) or both
  2. Neuropathy of any cause other than diabetes mellitus which might interfere with the assessment of the severity of dPNP Other neurologic diseases that may produce weakness, sensory loss, or autonomic symptoms or test abnormality which might interfere with the assessment of the severity of dPNP Myopathy of any cause which might interfere with the assessment of the severity of dPNP
  3. Peripheral vascular disease severe enough to cause intermittent claudication or ischemic ulcers or limb ischemia
  4. Patients with a history of ophthalmological findings suggesting a high risk for visual loss i.e., significant maculopathy or proliferative retinopathy
  5. Psychiatric, psychological, or behavioural symptoms that would interfere with the patient's ability to participate in the trial
  6. Patients with any active neoplastic disease except basal cell carcinoma
  7. Patients with atrial fibrillation unless controlled and stabilised by medication (changed to this criterion by Amendment 1)
  8. Patients with clinically significant cardiac, pulmonary, gastrointestinal, hematologic, or endocrine disease (other than diabetes) that may confound interpretation of the study results or prevent the patient from completing the study
  9. Patients who have had organ transplants of any kind
  10. Patients with significant hepatic or renal disease (ASAT or ALAT >2 times normal, serum creatinine >1.8 mg/dL (>159 µmol/l) for males or >1.6 mg/dL (>141 µmol/l) for females)
  11. Patients with a recent history (within last 12 months) of drug or alcohol abuse
  12. Use of any investigational drug within the last 6 months
  13. History of severe or anaphylactic reaction to multiple drugs, sulfur products, or biologic products (changed to this criterion by Amendment 1)
  14. Ketoacidosis or hypoglycaemia within last 3 months resulting in hospital admission
  15. Antioxidant therapy (vitamins E > 400IU, C > 200mg, and beta-Carotene > 30mg) or pentoxyphylline within last 1 month before start of trial
  16. Use of evening primrose oil or any other gamma-linolenic acid containing substance within the last 3 months
  17. Use of thioctic acid > 50mg/day within last 3 months
  18. History of use of medications or vitamins known to cause peripheral neuropathy including but not limited to use of phenytoin or carbamazepine over 15 or more years, or use of pyridoxine > 100mg/d within the past 12 months
  19. Bilateral sural nerve biopsies
  20. Existing foot ulcers
  21. Pregnant or lactating females
  22. Continued use of medications listed in protocol 6.3.3 (first paragraph)
  23. Medication non-compliance (deviation of more than ±10% of dosages to be taken (1 tablet/day))
Sexes Eligible for Study: All
18 Years to 64 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Croatia,   Denmark,   France,   Italy,   Netherlands,   Spain,   Sweden,   United Kingdom,   United States
Not Provided
Not Provided
Dr. Joachim Maus, MEDA Pharma GmbH & Co. KG
MEDA Pharma GmbH & Co. KG
  • Clinquest, Inc.
  • Ergomed
  • Quintiles, Inc.
Principal Investigator: Peter James Dyck Mayo Clinic, Dept. of Neurology, 200 First Street Southwest, Rochester, MN 55905, USA
MEDA Pharma GmbH & Co. KG
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP